Novartis Pharma US

         LESCOL® XL Tolerability

Studies have shown that LESCOL® XL offers proven safety and tolerability:

  • Is effective and has demonstrated proven safety and tolerability profile in a large cohort of elderly patients.1

LESCOL® XL also has a low rate of CK elevations - compared to placebo

   
   
 

*Controlled trials with LESCOL® Capsules (20 and 40 mg daily and 40 mg twice daily).
†Controlled trials with LESCOL® XL 80 mg Tablets.
 


References:
1. Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol. 2003; 12:225-231.
2. Benghozi R, Bortolini M, Jai Y, Isaccsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol. 2002;89:231-233.
3. LESCOL® XL full Prescribing Information.

   
 
 
Professionals Main Page  |  LESCOL® XL Sample Request  |  XL Everyday Patients Program
Slide Deck  |  Efficacy  |  Tolerability  |  Dosing  |  LESCOL® XL Clinical Study
Prescribing Information

LESCOL® XL Home
Contact Us  |  Site Guide  |  Site Map
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2010 Novartis Pharmaceuticals Corporation. All rights reserved.

Novartis proudly supports the Together Rx Access program.		 Together Rx Access